John Saathoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John Saathoff has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aline Nunes De Souza
Virginia Commonwealth University
1 shared publication - Anand Shinde
Virginia Commonwealth University
1 shared publication - B. Frank Gupton
Virginia Commonwealth University
1 shared publication - Barrack Stubbs
Virginia Commonwealth University
1 shared publication - Daryl Guthrie
Virginia Commonwealth University
1 shared publication Glen E. Kellogg
Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A Concise Route to Lenacapavir Sodium: First Demonstration of One-Pot Heck-Suzuki Coupling in Lenacapavir API Synthesis
This article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both treatment of multi-drug resistant HIV (Sunlenca®, 2022) and PrEP (Yeztugo®, 2025). Previous medicinal chemistry synthetic routes relied on separate Pd-catalyzed cou-plings and involved atropisomeric intermediates, resulting in low efficiency. Gilead’s 2024 four-step process improved scalability but retained discrete Pd-catalyzed steps and early-stage incorporation of the costly chiral pyrazole carboxylic acid (Frag C). Our streamlined approach begins with a chiral bromopyridine (Frag A) and features a telescoped Heck-Suzuki coupling and late-stage amidation with Frag C. This marks the first reported one-pot Heck-Suzuki sequence in the synthesis of lenacapavir, minimizing atropisomer handling and simplifying Pd sequestration. The process yields lenaca-pavir API in 50–55% overall yield, with >99.9 wt% purity, and Pd content below 4.2 ppm.
- 30 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Concise Route to Lenacapavir Sodium: First Demonstration of One-Pot Heck-Suzuki Coupling in Lenacapavir API Synthesis
This article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both treatment of multi-drug resistant HIV (Sunlenca®, 2022) and PrEP (Yeztugo®, 2025). Previous medicinal chemistry synthetic routes relied on separate Pd-catalyzed cou-plings and involved atropisomeric intermediates, resulting in low efficiency. Gilead’s 2024 four-step process improved scalability but retained discrete Pd-catalyzed steps and early-stage incorporation of the costly chiral pyrazole carboxylic acid (Frag C). Our streamlined approach begins with a chiral bromopyridine (Frag A) and features a telescoped Heck-Suzuki coupling and late-stage amidation with Frag C. This marks the first reported one-pot Heck-Suzuki sequence in the synthesis of lenacapavir, minimizing atropisomer handling and simplifying Pd sequestration. The process yields lenaca-pavir API in 50–55% overall yield, with >99.9 wt% purity, and Pd content below 4.2 ppm.